Minimal and null predictive effects for the most popular blood biomarkers of cardiovascular disease

Circulation Research

Volumn 110, Issue 5, 2012, Pages 658-662

  Ioannidis, John P A ^a   Tzoulaki, Ioanna ^b,c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF IOANNINA   (Greece)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; FIBRINOGEN; HOMOCYSTEINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MYELOPEROXIDASE; SERUM ALBUMIN; TRIACYLGLYCEROL; URIC ACID;

ALBUMIN BLOOD LEVEL; ANGINA PECTORIS; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; FIBRINOGEN BLOOD LEVEL; GENOTYPE; HUMAN; HYPERTENSION; MYOCARDIAL DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; HUMANS; MODELS, CARDIOVASCULAR; PREDICTIVE VALUE OF TESTS; RISK FACTORS;

EID: 84857834833     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/RES.0b013e31824da8ad     Document Type: Review

References (53)

1. Hlatky MA, Greenland P, Arnett DK, et al. American Heart Association Expert Panel on Subclinical Atherosclerotic Diseases and Emerging Risk Factors and the Stroke Council. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association [published correction appears in Circulation. 2009;119: e606].
2. Circulation. 2009;119:2408-2416.
3. Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation. 2006;113:2335-2362. (Pubitemid 43947980)
4. Tzoulaki I, Siontis KC, Ioannidis JP. Prognostic effect size of cardiovascular biomarkers in datasets from observational studies versus randomised trials: meta-epidemiology study. BMJ. 2011;343:d6829.
5. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-1847. (Pubitemid 28213628)
6. Kavvoura FK, Liberopoulos G, Ioannidis JP. Selection in reported epidemiological risks: an empirical assessment. PLoS Med. 2007;4:e79.
7. Ioannidis JP, Panagiotou OA. Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses. JAMA. 2011;305:2200-2210.
8. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation. 2007;115:928-935. (Pubitemid 46294733)
9. Pepe MS, Janes H, Longton G, Leisenring W, Newcomb P. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol. 2004;159:882-890. (Pubitemid 38657490)
10. Siontis GC, Ioannidis JP. Risk factors and interventions with statistically significant tiny effects. Int J Epidemiol. 2011;40:1292-1307.
11. Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and coronary heart disease: a systematic review and metaanalysis. Arthritis Care Res (Hoboken). 2010;62:170-180.
12. Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, Carpenter J, Rücker G, Harbord RM, Schmid CH, Tetzlaff J, Deeks JJ, Peters J, Macaskill P, Schwarzer G, Duval S, Altman DG, Moher D, Higgins JP. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002.
13. Wheeler JG, Juzwishin KD, Eiriksdottir G, Gudnason V, Danesh J. Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: prospective study and meta-analysis. PLoS Med. 2005;2:e76.
14. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. 2007;297:611-619.
15. Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation. 2008;118: 2243-2251.
16. Elliott P, Chambers JC, Zhang W, et al. Genetic loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA. 2009;302:37-48.
17. Wensley F, Gao P, Burgess S, Kaptoge S, et al. Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ. 2011;342:d548.
18. Keavney B, Danesh J, Parish S, Palmer A, Clark S, Youngman L, Delépine M, Lathrop M, Peto R, Collins R. Fibrinogen and coronary heart disease: test of causality by "Mendelian randomization." Int J Epidemiol. 2006;35:935-943. (Pubitemid 44540744)
19. Greenland P, Alpert JS, Beller GA, et al. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2010;122:e584-e636.
20. Myers GL, Christenson RH, Cushman M, Ballantyne CM, Cooper GR, Pfeiffer CM, Grundy SM, Labarthe DR, Levy D, Rifai N, Wilson PW; NACB LMPG Committee Members. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: emerging biomarkers for primary prevention of cardiovascular disease. Clin Chem. 2009;55:378-384.
21. Pencina MJ, D'Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med. 2011;30:11-21.
22. Pepe MS, Janes H. Commentary: reporting standards are needed for evaluations of risk reclassification. Int J Epidemiol. 2011;40:1106-1108.
23. Pepe MS. Problems with risk reclassification methods for evaluating prediction models. Am J Epidemiol. 2011;173:1327-1335.
24. Tzoulaki I, Liberopoulos G, Ioannidis JP. Assessment of claims of improved prediction beyond the Framingham risk score. JAMA. 2009; 302:2345-2352.
25. Tzoulaki I, Liberopoulos G, Ioannidis JP. Use of reclassification for assessment of improved prediction: an empirical evaluation. Int J Epidemiol. 2011;40:1094-1105.
26. Mueller C, Scholer A, Laule-Kilian K, Martina B, Schindler C, Buser P, Pfisterer M, Perruchoud AP. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med. 2004;350: 647-654. (Pubitemid 38364623)
27. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.
28. Wald DS, Morris JK, Wald NJ. Reconciling the evidence on serum homocysteine and ischaemic heart disease: a meta-analysis. PLoS One. 2011;6:e16473.
29. Holmes MV, Newcombe P, Hubacek JA, et al. Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials. Lancet. 2011;378:584-594.
30. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG. MTHFR 677C3T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA. 2002;288:2023-2031. (Pubitemid 35204693)
31. Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol. 2007;49:2129-2138. (Pubitemid 46783865)
32. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation. 2004;109(suppl II):II-2-II-10. (Pubitemid 38724149)
33. Andraws R, Berger JS, Brown DL. Effects of antibiotic therapy on outcomes of patients with coronary artery disease: a meta-analysis of randomized controlled trials. JAMA. 2005;293:2641-2647. (Pubitemid 40741201)
34. Ntzani EE, Rizos EC, Ioannidis JP. Genetic effects versus bias for candidate polymorphisms in myocardial infarction: case study and overview of large-scale evidence. Am J Epidemiol. 2007;165:973-984. (Pubitemid 46598826)
35. Morgan TM, Krumholz HM, Lifton RP, Spertus JA. Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study. JAMA. 2007;297:1551-1561. (Pubitemid 46588368)
36. International Consortium for Blood Pressure Genome-Wide Association Studies; Ehret GB, Munroe PB, et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011; 478:103-109.
37. Schunkert H, König IR, Kathiresan S, et al. CARDIoGRAM Consortium. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet. 2011;43:333-338.
38. Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 2010;466: 707-713.
39. Young NS, Ioannidis JP, Al-Ubaydli O. Why current publication practices may distort science. PLoS Med. 2008;5:e201.
40. Emerging Risk Factors Collaboration; Danesh J, Erqou S, et al. The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol. 2007; 22:839-869.
41. Ioannidis JP, Bernstein J, Boffetta P, et al. A network of investigator networks in human genome epidemiology. Am J Epidemiol. 2005;162: 302-304. (Pubitemid 41389711)
42. Preuss M, Konig IR, Thompson JR, et al. CARDIoGRAM Consortium. Design of the Coronary ARtery DIsease Genome-Wide Replication And Meta-Analysis (CARDIoGRAM) Study: a genome-wide association meta-analysis involving more than 22 000 cases and 60 000 controls. Circ Cardiovasc Genet. 2010;3:475-483.
43. Seminara D, Khoury MJ, O'Brien TR, et al. Human Genome Epidemiology Network; Network of Investigator Networks. The emergence of networks in human genome epidemiology: challenges and opportunities. Epidemiology. 2007;18:1-8. (Pubitemid 46005900)
44. Medicare Laboratory Fee Schedule. https://www.cms.gov/ClinicalLabFee Sched/02+clinlab.asp. Accessed January 20, 2012.
45. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, Collins R, Thompson SG, Danesh J; Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302:1993-2000.
46. Kaptoge S, Di AE, Lowe G, Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J; Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375:132-140.
47. Danesh J, Lewington S, Thompson SG, et al. Fibrinogen Studies Collaboration. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis [published correction appears in JAMA. 2005;294:2848]
48. JAMA. 2005;294:1799-1809.
49. Danesh J, Kaptoge S, Mann AG, Sarwar N, Wood A, Angleman SB, Wensley F, Higgins JP, Lennon L, Eiriksdottir G, Rumley A, Whincup PH, Lowe GD, Gudnason V. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med. 2008;5:e78.
50. Di AE, Chowdhury R, Sarwar N, Ray KK, Gobin R, Saleheen D, Thompson A, Gudnason V, Sattar N, Danesh J. B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circulation. 2009;120:2177-2187.
51. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA. 1998;279: 1477-1482. (Pubitemid 28228207)
52. Malik I, Danesh J, Whincup P, Bhatia V, Papacosta O, Walker M, Lennon L, Thomson A, Haskard D. Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet. 2001;358:971-976.
53. Humphrey LL, Fu R, Rogers K, Freeman M, Helfand M. Homocysteine level and coronary heart disease incidence: a systematic review and meta-analysis. Mayo Clin Proc. 2008;83:1203-1212.